These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23082785)

  • 1. Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia.
    Sakata K; Morita T
    BMC Urol; 2012 Oct; 12():29. PubMed ID: 23082785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of silodosin on sexual function - realistic picture from the everyday clinical practice.
    Capogrosso P; Serino A; Ventimiglia E; Boeri L; Dehò F; Damiano R; Briganti A; Montorsi F; Salonia A
    Andrology; 2015 Nov; 3(6):1076-81. PubMed ID: 26446512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing Aspects of Male Sexual Functions Accompanying Treatment of Benign Prostatic Hyperplasia With Silodosin 8 mg Per Day.
    ; Cihan A; Kazaz İO; Yıldırım Ö; Deliktaş H; Ongün Ş; Gül Ü; Şahin B; Üre İ; Özkara H
    J Sex Med; 2020 Jun; 17(6):1094-1100. PubMed ID: 32217036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silodosin causes impaired ejaculation and enlargement of seminal vesicles in sexually active men treated for lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Bozkurt O; Demir O; Sen V; Esen A
    Urology; 2015 May; 85(5):1085-1089. PubMed ID: 25744372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia.
    Homma Y; Kawabe K; Takeda M; Yoshida M
    Urology; 2010 Dec; 76(6):1446-50. PubMed ID: 20472263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Miyakita H; Yokoyama E; Onodera Y; Utsunomiya T; Tokunaga M; Tojo T; Fujii N; Yanada S
    Int J Urol; 2010 Oct; 17(10):869-75. PubMed ID: 20735791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH.
    Osman NI; Chapple CR; Tammela TL; Eisenhardt A; Oelke M
    World J Urol; 2015 May; 33(5):697-706. PubMed ID: 25712312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
    Kawabe K; Yoshida M; Homma Y;
    BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Investigation of adverse events and the continuance rate of silodosin in all patients who received silodosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasia].
    Furuya R; Masumori N; Furuya S; Ogura H; Mutoh M; Kobayashi K; Hisasue S; Tsukamoto T
    Nihon Hinyokika Gakkai Zasshi; 2010 Jan; 101(1):13-7. PubMed ID: 20158073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia.
    Yokoyama T; Hara R; Fukumoto K; Fujii T; Jo Y; Miyaji Y; Nagai A; Sone A
    Int J Urol; 2011 Mar; 18(3):225-30. PubMed ID: 21272091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported ejaculatory function and satisfaction in men with lower urinary tract symptoms/benign prostatic hyperplasia.
    Cho MC; Kim JK; Song SH; Cho SY; Lee SW; Kim SW; Paick JS
    Asian J Androl; 2018; 20(1):69-74. PubMed ID: 28474611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical significance of abnormal ejaculation by silodosin. Is it important?
    Akgül M; Yazıcı C; Şipal T; Arda E
    Andrologia; 2021 Aug; 53(7):e14086. PubMed ID: 33951747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
    Yu HJ; Lin AT; Yang SS; Tsui KH; Wu HC; Cheng CL; Cheng HL; Wu TT; Chiang PH
    BJU Int; 2011 Dec; 108(11):1843-8. PubMed ID: 21592295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe].
    Chapple ChR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernandez Fernandez E
    Urologiia; 2012; (5):38-42, 44-5. PubMed ID: 23342615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silodosin: erectile and ejaculatory disorders.
    Prescrire Int; 2012 May; 21(127):129. PubMed ID: 22844684
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis.
    Gacci M; Ficarra V; Sebastianelli A; Corona G; Serni S; Shariat SF; Maggi M; Zattoni F; Carini M; Novara G
    J Sex Med; 2014 Jun; 11(6):1554-66. PubMed ID: 24708055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.
    Manjunatha R; Pundarikaksha HP; Madhusudhana HR; Amarkumar J; Hanumantharaju BK
    Indian J Pharmacol; 2016; 48(2):134-40. PubMed ID: 27127315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silodosin and its potential for treating premature ejaculation: a preliminary report.
    Sato Y; Tanda H; Nakajima H; Nitta T; Akagashi K; Hanzawa T; Tobe M; Haga K; Uchida K; Honma I
    Int J Urol; 2012 Mar; 19(3):268-72. PubMed ID: 22188258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
    Novara G; Chapple CR; Montorsi F
    BJU Int; 2014 Sep; 114(3):427-33. PubMed ID: 24571313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silodosin: a review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia.
    Keating GM
    Drugs; 2015 Feb; 75(2):207-17. PubMed ID: 25575983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.